ClinicalTrials.gg
CompletedNCT01758198Updated May 15, 2017

Abatacept Post-marketing Clinical Study in Japan

A Phase 4 interventional study of Abatacept and Placebo matching with Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 74 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
14th of 63
405 · median 119
Started
2013
with 4 others
Phase 4
16 of 63
none open now
Registered
34th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 14th largest by enrollment, is one of 5 that started in 2013, is one of 16 in phase 4, and was the 34th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to compare the clinical efficacy including joint damage progression and safety of Abatacept plus Methotrexate (MTX) to placebo plus MTX.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MTX inadequate responder
  • Biologic Naïve
  • Functional class I, II or III
  • ≥6 swollen and ≥6 tender joints
  • C-reactive protein (CRP) ≥2.0mg/dl or erythrocyte sedimentation rate (ESR) ≥28 mm/hr
  • Anti-cyclic citrullinated peptide (CCP) antibody positive
  • Have erosion

Exclusion criteria

Exclusion Criteria:

  • Any other rheumatic disease
  • Active angiitis on main organs excluding rheumatoid nodule
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Group 1: Abatacept + Methotrexate (MTX)

    Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months Methotrexate ≥6 mg/week for 12 months

    Biological: Abatacept · Drug: Methotrexate

  • Placebo comparator
    Group 2: Placebo matching with Abatacept + Methotrexate

    Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months Methotrexate ≥6 mg/week for 12 months

    Drug: Placebo matching with Abatacept · Drug: Methotrexate

Interventions

  • BiologicalAbatacept

    Also known as: BMS-188667 (Orencia)

  • DrugPlacebo matching with Abatacept
06

What researchers measure

Primary outcomes

  1. American College of Rheumatology (ACR) 20% response rate

    Time frame: 4 months (week 16)

  2. Change from baseline in Total Sharp Score (TSS) using the Modified van der Heijde Sharp (vdH-S) method to 6 months (Week 24)

    Time frame: Baseline (Day 1), 6 months (Week 24)

Secondary outcomes

  1. Change from baseline in Disease Activity Score-28 (DAS28)-CRP to 4 months (Week16)

    Time frame: Baseline (Day 1), 4 months (Week 16)

  2. Non-progressors rate for the structural damage

    The non-progressors rate is defined as the proportion of subjects meeting the change from baseline in the TSS at 6 months less than or equal to the smallest detectable difference (SDD) and/or the smallest detectable change (SDC)

    Time frame: Baseline (Day 1), 6 months (Week 24)

  3. ACR 50 response rates

    Time frame: 4 months (Week16)

  4. ACR 70 response rates

    Time frame: 4 months (Week16)

  5. Safety and tolerability will be measured based on clinical Adverse Events, vital signs, and laboratory abnormalities

    Time frame: 12 months (Week52)

07

Study locations

74 sites
  • Local Institution
    Kamogawa-city, Chiba 296-8602, Japan
  • Local Institution
    Kasamatsu-town, Gifu 501-6061, Japan
  • Local Institution
    Kakogawa-city, Hyogo 675-8611, Japan
  • Local Institution
    Yokohama-city, Kanagawa 245-8575, Japan
  • Local Institution
    Kurashiki-city, Okayama 710-8602, Japan
  • Local Institution
    Izumisano-city, Osaka 598-0048, Japan
  • Local Institution
    Fujieda-city, Shizuoka 426-8677, Japan
  • Local Institution
    Toyama-city, Toyama 930-8550, Japan
  • Local Institution
    Shimonoseki-city, Yamaguchi 750-8520, Japan
  • Local Institution
    Asahi, 289-2511, Japan
  • Local Institution
    Fuchu, 183-8524, Japan
  • Local institution
    Fukuoka, 810-8563, Japan
  • Local Institution
    Fukuoka, 813-0017, Japan
  • Local institution
    Funabashi, 274-0053, Japan
  • Local Institution
    Hakodate, 040-8611, Japan
  • Local Institution
    Hiroshima, 734-8551, Japan
  • Local Institution
    Hitachi, 316-0015, Japan
  • Local institution
    Hokkaido, 078-8243, Japan
  • Local Institution
    Iizuka, 820-8505, Japan
  • Local Institution
    Kagoshima, 890-0067, Japan
  • Local Institution
    Kagoshima, 891-0133, Japan
  • Local Institution
    Kanazawa, 920-8616, Japan
  • Local Institution
    Kasama, 309-1793, Japan
  • Local Institution
    Kato, 673-1462, Japan
  • Local Institution
    Kitakyushu, 800-0031, Japan
  • Local Institution
    Kitakyushu, 800-0296, Japan
  • Local Institution
    Kitakyushu, 807-8556, Japan
  • Local Institution
    Kitamoto, 364-8501, Japan
  • Local institution
    Kobe, 650-0017, Japan
  • Local institution
    Kobe, 654-0047, Japan
  • Local Institution
    Kochi, 781-0112, Japan
  • Local Institution
    Koshi, 861-1196, Japan
  • Local institution
    Kumamoto, 862-0976, Japan
  • Local Institution
    Matsumoto, 390-8601, Japan
  • Local Institution
    Nagano, 380-8582, Japan
  • Local Institution
    Nagaoka, 940-2085, Japan
  • Local Institution
    Nagasaki, 850-0832, Japan
  • Local Institution
    Nagoya, 460-0001, Japan
  • Local Institution
    Nagoya, 466-8560, Japan
  • Local Institution
    Narashino, 275-0006, Japan
  • Local Institution
    Narita, 286-0041, Japan
  • Local Institution
    Okayama, 700-8607, Japan
  • Local institution
    Osaka, 545-8585, Japan
  • Local Institution
    Osaki, 989-6183, Japan
  • Local institution
    Oume, 198-0042, Japan
  • Local institution
    Sapporo, 001-0907, Japan
  • Local Institution
    Sapporo, 060-0001, Japan
  • Local Institution
    Sapporo, 060-8648, Japan
  • Local Institution
    Sapporo, 063-0811, Japan
  • Local Institution
    Sasebo, 857-1195, Japan
  • Local Institution
    Sayama, 350-1305, Japan
  • Local Institution
    Sendai, 980-6116, Japan
  • Local Institution
    Sendai, 982-0032, Japan
  • Local Institution
    Sendai, 983-8512, Japan
  • Local Institution
    Shizuoka, 420-0821, Japan
  • Local Institution
    Takaoka, 933-0874, Japan
  • Local Institution
    Takasaki, 370-0053, Japan
  • Local institution
    Tokyo, 101-0062, Japan
  • Local Institution
    Tokyo, 104-8560, Japan
  • Local Institution
    Tokyo, 130-8575, Japan
  • Local Institution
    Tokyo, 160-8582, Japan
  • Local Institution
    Tokyo, 162-8543, Japan
  • Local Institution
    Tokyo, 162-8655, Japan
  • Local Institution
    Tokyo, 170-8476, Japan
  • Local Institution
    Tokyo, 173-8610, Japan
  • Local Institution
    Tokyo, 174-0071, Japan
  • Local Institution
    Tokyo, 179-0072, Japan
  • Local Institution
    Tomakomai, 053-0018, Japan
  • Local Institution
    Toyama, 930-0138, Japan
  • Local Institution
    Toyama, 930-0194, Japan
  • Local Institution
    Utsunomiya, 321-0964, Japan
  • Local institution
    Yokohama, 231-8682, Japan
  • Local institution
    Yokohama, 236-0004, Japan
  • Local Institution
    Yotsukaido, 284-0003, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Dec 2016, 44 months.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2012
First posted
Jan 1, 2013
StartActual
Apr 11, 2013
Primary completionActual
Dec 26, 2016
CompletionActual
Dec 26, 2016
Last update
May 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01758198
Responsible party
Sponsor
First posted
Jan 1, 2013
Start date
Apr 11, 2013
Primary completion
Dec 26, 2016
Completion
Dec 26, 2016
Last update
May 15, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion